These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 15619613

  • 1. New possibilities in anticoagulant management of atrial fibrillation.
    Waldo AL.
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S30-8. PubMed ID: 15619613
    [Abstract] [Full Text] [Related]

  • 2. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL, SPORTIF Investigators.
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [Abstract] [Full Text] [Related]

  • 3. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H, Selçuk MT, Maden O.
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [Abstract] [Full Text] [Related]

  • 4. [New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins].
    Scardi S, Giansante C.
    Ital Heart J Suppl; 2004 Sep; 5(9):705-11. PubMed ID: 15568608
    [Abstract] [Full Text] [Related]

  • 5. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW, SPORTIF Investigators.
    Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [Abstract] [Full Text] [Related]

  • 6. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL.
    J Am Coll Cardiol; 2005 Jan 04; 45(1):1-9. PubMed ID: 15629364
    [Abstract] [Full Text] [Related]

  • 7. Ximelagatran: a new oral anticoagulant.
    Hrebickova L, Nawarskas JJ, Anderson JR.
    Heart Dis; 2003 Jan 04; 5(6):397-408. PubMed ID: 14633322
    [Abstract] [Full Text] [Related]

  • 8. Ximelagatran for stroke prevention in atrial fibrillation.
    Boos CJ, Lip GY.
    Expert Rev Cardiovasc Ther; 2005 Jul 04; 3(4):551-63. PubMed ID: 16076267
    [Abstract] [Full Text] [Related]

  • 9. Preventing stroke in atrial fibrillation: the SPORTIF programme.
    Lip GY.
    Pathophysiol Haemost Thromb; 2005 Jul 04; 34 Suppl 1():25-30. PubMed ID: 15812201
    [Abstract] [Full Text] [Related]

  • 10. Preventing stroke in patients with atrial fibrillation: current treatments and new concepts.
    Connolly SJ.
    Am Heart J; 2003 Mar 04; 145(3):418-23. PubMed ID: 12660663
    [Abstract] [Full Text] [Related]

  • 11. [Preventing cerebrovascular accidents during atrial fibrillation].
    Ederhy S, Meuleman C, Hammoudi N, Janower S, Boccara F, Cohen A.
    Presse Med; 2005 Oct 22; 34(18):1315-24. PubMed ID: 16269996
    [Abstract] [Full Text] [Related]

  • 12. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J.
    Arch Intern Med; 2006 Apr 24; 166(8):853-9. PubMed ID: 16636210
    [Abstract] [Full Text] [Related]

  • 13. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC, Executive Steering Committee of the SPORTIFF III and V Investigators.
    Cerebrovasc Dis; 2006 Apr 24; 21(4):279-93. PubMed ID: 16449807
    [Abstract] [Full Text] [Related]

  • 14. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB, Halperin JL.
    Semin Vasc Med; 2005 Aug 24; 5(3):285-92. PubMed ID: 16123916
    [Abstract] [Full Text] [Related]

  • 15. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL, Executive Steering Committee, SPORTIF III and V Study Investigators.
    Am Heart J; 2003 Sep 24; 146(3):431-8. PubMed ID: 12947359
    [Abstract] [Full Text] [Related]

  • 16. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL.
    Expert Rev Cardiovasc Ther; 2004 Mar 24; 2(2):163-74. PubMed ID: 15151465
    [Abstract] [Full Text] [Related]

  • 17. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era..
    Mohapatra R, Tran M, Gore JM, Spencer FA.
    Am Heart J; 2005 Jul 24; 150(1):19-26. PubMed ID: 16084146
    [Abstract] [Full Text] [Related]

  • 18. Trials and tribulations of non-inferiority: the ximelagatran experience.
    Kaul S, Diamond GA, Weintraub WS.
    J Am Coll Cardiol; 2005 Dec 06; 46(11):1986-95. PubMed ID: 16325029
    [Abstract] [Full Text] [Related]

  • 19. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials.
    Ford GA, Choy AM, Deedwania P, Karalis DG, Lindholm CJ, Pluta W, Frison L, Olsson SB, SPORTIF III, V Investigators.
    Stroke; 2007 Nov 06; 38(11):2965-71. PubMed ID: 17885258
    [Abstract] [Full Text] [Related]

  • 20. Ximelagatran in prevention of cardiovascular events.
    Molckovsky D, Boucher M.
    Issues Emerg Health Technol; 2004 Nov 06; (62):1-4. PubMed ID: 15565751
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.